“GLP-1s wreck your bones and cause osteoporosis.”
What the evidence shows
Losing a lot of weight by any method tends to lower bone mineral density (BMD) somewhat — a lighter skeleton is loaded less, and rapid loss can increase bone turnover. GLP-1s share this. In a 2024 phase 2 trial in adults at increased fracture risk, 52 weeks of once-weekly semaglutide modestly reduced bone density at the hip and spine versus placebo, which the authors attributed largely to the accompanying weight loss (about 6.8 kg more than placebo). Crucially, that's not the same as "osteoporosis": a meta-analysis of 44 randomized trials found fracture risk was not increased and was actually *lower* with GLP-1 drugs (relative risk about 0.77), with the benefit related to longer treatment.
What we still don’t know
The trials weren't designed or long enough to settle real-world fracture outcomes, so a small effect over many years can't be excluded — especially in older adults, post-menopausal women, or people who already have low bone mass. How much resistance training, adequate protein, calcium/vitamin D, and a slower pace of loss protect bone in this specific setting is plausible but not firmly quantified.
Why the claim misleads
"Wreck your bones / cause osteoporosis" inflates a modest, weight-loss-linked dip in bone density into a diagnosed bone disease and a fracture epidemic the fracture data don't show. The measured BMD change is real and worth managing — bone-protective habits and monitoring matter, particularly for people already at risk — but it is not evidence the drug is dissolving the skeleton.
Graded by The Peptide Era · evidence, not hype